Bryan Johnson, the tech entrepreneur behind the “Blueprint” project, continues to dominate discussions in the longevity and biohacking communities. Recent coverage in top publications, including *The New York Times*, *MIT Technology Review*, and *Bloomberg*, highlights the evolving data from his decade-long experiment and the growth of his neurotechnology company, Kernel. According to the latest biological age assessments, Johnson has reportedly reversed some epigenetic markers by 36 years. However, he acknowledges the complexity of interpreting this data and notes it doesn’t directly translate to feeling younger.

The Blueprint protocol, which costs over $2 million annually, involves a rigorous regimen of more than 100 daily interventions. These include a controlled diet of around 2,500 calories, primarily plant-based, intense exercise, sleep optimization, frequent blood testing, pharmaceutical interventions, and exposure to extreme temperatures. Meanwhile, Kernel is making strides with its non-invasive Flow headset, designed to measure cerebral blood flow and detect early signs of neurological decline. The company has secured additional funding and is expanding its research into areas beyond aging, such as traumatic brain injury and mental health.

Critics within the scientific community remain skeptical, citing the limitations of epigenetic age testing and the potential for placebo effects due to Johnson’s intense focus and significant financial investment. Concerns about the accessibility and ethics of extreme longevity pursuits are also raised, highlighting the vast disparity between Johnson’s resources and the average person’s ability to implement his protocol.

Johnson frames Blueprint as a data-driven exploration aimed at improving healthspan – the period of life spent in good health – for everyone, rather than a personal quest for immortality. He is increasingly emphasizing the importance of open-sourcing the data generated from his experiment to contribute to a broader understanding of aging and potentially democratize access to longevity strategies. Kernel is also shifting its focus towards making its technology more user-friendly and affordable, with plans to release a consumer version of the Flow headset at a lower price point.

As Johnson continues his self-experimentation and Kernel advances its technology, the boundaries of longevity research are being pushed, sparking debate and inspiring further investigation into the science of aging. However, questions about the validity, ethics, and accessibility of Johnson’s approach persist.